Management of Patients With Atrial Fibrillation

Publication Date: November 30, 2023
Last Updated: July 12, 2024

Introduction

2.5. Addressing Health Inequities and Barriers to AF Management

1. Patients with AF, regardless of sex and gender diversity, race and ethnicity, or adverse social determinants of health (SDOH),* should be equitably offered guideline-directed stroke risk reduction therapies as well as rate or rhythm control strategies and LRFM as indicated to improve QOL and prevent adverse outcomes. (1, B-NR)
* Including lower income, lower education, inadequate or lack of insurance coverage, or rurality.
3594638

Management

4.2. Basic Evaluation

4.2.1. Basic Clinical Evaluation

1. In patients with newly diagnosed AF, a transthoracic echocardiogram to assess cardiac structure, laboratory testing to include a complete blood count, metabolic panel, and thyroid function, and testing to assess for other medical conditions associated with AF are recommended to determine stroke and bleeding risk factors, as well as underlying conditions that will guide further management. (1, B-NR)
3594638
2. In patients with newly diagnosed AF, protocolized testing for ischemia, acute coronary syndrome (ACS), and pulmonary embolism (PE) should not routinely be performed to assess the etiology of AF unless there are additional signs or symptoms to indicate those disorders. (3 - No Benefit, B-NR)
3594638

4.2.2. Rhythm Monitoring Tools and Methods

1. Among individuals without a known history of AF, it is recommended that an initial AF diagnosis be made by a clinician using visual interpretation of the electrocardiographic signals, regardless of the type of rhythm or monitoring device. (1, B-NR)
3594638
2. In patients with an intracardiac rhythm device capable of a diagnosis of AF, such as from an atrial pacemaker lead, a diagnosis of AF should only be made after it is visually confirmed by reviewing intracardiac tracings in order to exclude signal artifacts and other arrhythmias. (1, B-NR)
3594638
3. For patients who have had a systemic thromboembolic event without a known history of AF and in whom maximum sensitivity to detect AF is sought, an implantable cardiac monitor is reasonable. (2a, B-R)
3594638
4. Among patients with a diagnosis of AF, it is reasonable to infer AF frequency, duration, and burden using automated algorithms available from electrocardiographic monitors, implantable cardiac monitors, and cardiac rhythm devices with an atrial lead, recognizing that periodic review can be required to exclude other arrythmias. (2a, B-NR)
3594638

5. Among patients with AF in whom cardiac monitoring is advised, it is reasonable to recommend use of a consumer-accessible electrocardiographic device that provides a high-quality tracing to detect recurrences.

(2a, B-R)
3594638

Overview

Title

Management of Patients With Atrial Fibrillation

Authoring Organizations

American College of Cardiology

American Heart Association

Heart Rhythm Society

American College of Clinical Pharmacy